{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:09:14Z","timestamp":1793250554407,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:31:27Z","timestamp":1778023887000},"page":"1028.e1-1028.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Network Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8589-799X","authenticated-orcid":false,"given":"Gonzalo","family":"Bentolila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shernan","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9911","authenticated-orcid":false,"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annoek E.C.","family":"Broers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-6644","authenticated-orcid":false,"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Martinez","family":"Rolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2026.05.004_bib0001","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.004_bib0003","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/ajh.26320","article-title":"Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an <scp>HLA<\/scp>-matched sibling donor","volume":"96","author":"Cho","year":"2021","journal-title":"Am J Hematol"},{"issue":"29","key":"10.1016\/j.jtct.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.004_bib0005","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.jtct.2026.05.004_bib0006","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of Anti\u2013T-Lymphocyte globulin to assess impact on chronic graft-versus-host disease\u2013free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.004_bib0008","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.004_bib0011","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplantat"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.004_bib0012","article-title":"Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults","volume":"2023","author":"Chakupurakal","year":"2023","journal-title":"Cochrane Datab Syst Rev"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.24.00921","article-title":"Improved patient-reported outcomes with post-transplant cyclophosphamide: a quality-of-life evaluation and 2-year outcomes of BMT CTN 1703","volume":"43","author":"Holtan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.004_bib0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.05.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111985","article-title":"Updating the PRISMA reporting guideline for network meta-analysis: a scoping review","volume":"188","author":"Veroniki","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtct.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.004_bib0018","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.bbmt.2017.08.027","article-title":"Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis","volume":"23","author":"Gagelmann","year":"2017","journal-title":"Biol Blood Marrow Transplantat"},{"issue":"26","key":"10.1016\/j.jtct.2026.05.004_bib0021","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.004_bib0022","doi-asserted-by":"crossref","first-page":"40.e1","DOI":"10.1016\/j.jtct.2022.09.010","article-title":"ATG in HLA-matched, peripheral blood, hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a secondary analysis of a CIBMTR database","volume":"29","author":"Arcuri","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.05.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117071","article-title":"Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients","volume":"491","author":"Sharaf El-Deen","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.004_bib0025","doi-asserted-by":"crossref","first-page":"213.e1","DOI":"10.1016\/j.jtct.2023.11.020","article-title":"Post-transplantation cyclophosphamide and tacrolimus for graft-versus-host disease prevention after allogeneic hematopoietic cell transplantation from HLA-matched donors has more advantages than limitations","volume":"30","author":"Salas","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.004_bib0026","doi-asserted-by":"crossref","first-page":"695.e1","DOI":"10.1016\/j.jtct.2022.07.021","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"Battipaglia","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2020.271445","article-title":"Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation","volume":"107","author":"Massoud","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.004_bib0029","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00277-025-06199-z","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin in haploidentical stem cell transplantation: a systematic review and meta-analysis","volume":"104","author":"Jin","year":"2025","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.004_bib0030","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/0272989X20929309","article-title":"Comparison of methods for estimating therapy effects by indirect comparisons: a simulation study","volume":"40","author":"Weber","year":"2020","journal-title":"Med Decis Making"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.004_bib0031","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2026.05.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101080","article-title":"Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies","volume":"62","author":"Dul\u00e9ry","year":"2023","journal-title":"Blood Rev"},{"issue":"23","key":"10.1016\/j.jtct.2026.05.004_bib0033","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.004_bib0034","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","article-title":"Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation","volume":"7","author":"Ueda Oshima","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.004_bib0035","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching","volume":"56","author":"Irene","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.004_bib0036","doi-asserted-by":"crossref","first-page":"850.e1","DOI":"10.1016\/j.jtct.2022.09.001","article-title":"Bacterial bloodstream infections in patients undergoing allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.004_bib0037","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.jtct.2026.05.004_bib0038","article-title":"Risk of post-transplant cyclophosphamide-related cardiotoxicity in allogeneic stem cell transplantation","author":"Hadjali","year":"2026","journal-title":"Canadian J Cardiol"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.004_bib0039","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41375-025-02619-1","article-title":"GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party","volume":"39","author":"Penack","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.004_bib0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00277-021-04399-x","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis","volume":"100","author":"Gao","year":"2021","journal-title":"Ann Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:35:19Z","timestamp":1785414919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726003477"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Network Meta-Analysis of Randomized Trials to Determine Optimal GVHD Prophylaxis in Matched Sibling Donor Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}